|
 |
| home > epc > Winter 2004 |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EPC provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of EPC |
 |
| |
|
|
| In her Editor's Letter, Julia Lloyd-Parks reviews the latest offerings in this our Winter issue |
|
|
|
|
| In the first instalment of a regular series looking at the hottest issues in our industry as they happen, BearingPoint's Craig Wylie, Senior Manager, Life Sciences, and Hitesh A Anklesaria, Security Solutions Developer, take us through A SAFE Development - Secure Identity Evolves in Pharma |
|
|
Shortcomings in the management of risk can carry immense costs for pharmaceutical companies. Chris Buxton, Partner, and Evelyne Lemaire, Director at PricewaterhouseCoopers, thankfully are on board to provide a Risk Strategy: Managing Inwards and Communicating Outwards
|
|
|
| Robin Cammish, CEO of the QP Group, contends that procurement and supply represents a major opportunity for post-merger synergy and major savings, in Understanding Pharmaceutical Mergers and Acquisitions |
|
|
| Translating for the Pharma Industry: An Invisible Mission - Roberto Ganzerli, President and CEO of Arancho, discusses the complex, invaluable relationship between language service providers and pharmaceutical companies |
|
|
| In the pursuit of best practice as a way of life in the pharma sector, Glenn Van Dael, Manager in the Life Science Consulting Group at First Consulting Group, presents The Application of Change and Content Management to the Clinical Trials Process |
|
|
|
| Tom Ruane, Director of Patient Recruitment at Quintiles, offers his expertise in the search for efficient and streamlined Patient Recruitment: Integrated Services Provide the Key to Success |
|
|
| Don't Leave Patient Recruitment and Retention to Chance, exclaims John Dent, Patient Recruitment Director at (Pi) Patient interaction, as he presents us with three steps that, if implemented quickly, will certainly improve results |
|
|
| Emma Sergeant, President of Fast4wD Ogilvy, Clinical Trial Practice Worldwide, Nicky Sturt, Communications Director, and Gaynor Anders, Communications Director at Fast4wD Ogilvy Europe, mull over The Challenge of Participant Retention in Clinical Trials |
|
|
|
| With sponsors spending more money on larger trials for their drug candidates in the hope of weeding out drugs destined to fail before they enter expensive Phase II and III trials, Dries De Pauw, Global Business Manager, Clinical Research, at SGS Life Science Services, asserts the need for Putting Phase I in the Spotlight |
|
|
| Richmond Pharmacology brings together pharmaceutical industry representatives and leading cardiology opinion leaders to discuss The Definitive QTc Study - Notes from a Workshop |
|
|
|
|
| The Challenges of Implementing the European Clinical Trials Directive in the UK are reviewed by the MHRA's Brian Davis, Chairman of the Project Team responsible for implementing the Directive |
|
|
| Animal research currently provides essential guidance on how a medicine will act in the body, enabling scientists to bridge the gap between theory and practice. Dr Philip Wright, Director of Science & Technology at the ABPI, considers A Stark Choice: Stop Animal Research or Stop Developing New Medicines |
|
|
| Ben Rapinoja, Attorney and Hannu Jarvinen, Associate Lawyer at Attorneys at law Borenius & Kemppinen Ltd, assess the intricacies of Commercialising Academic Research - A Finnish Perspective |
|
|
|
| The pharmaceutical industry has been relatively absent in the dialogue about mainstreaming telecare - its voice now needs to be heard, argues Professor James Barlow, Chair in Technology and Innovation Management, Tanaka Business School, at Imperial College London, in Emerging Telecare Services - Implications for Pharmaceutical Companies |
|
|
| In Electronic Patient Reported Outcomes - Methods that Put Paper out to Dry and Quality First - Christine Lys, Director of Business Development at etrials Worldwide, examines why, despite serious technological advances, pharmaceutical companies have been slow to adopt and use eClinical tools |
|
|
|
|
| New Vaccines - Opportunities and Challenges? Dr V K Vinayak, Advisor/Consultant - New Initiative (R&D) at Panacea Biotech Ltd, gives us his perspective on the developments in this cornerstone of medical science |
|
|
| Dr Andreas Herrmann, Managing Director of Celonic, reflects on the steps to be considered in order to achieve a reliable process for drug production, in Process Development of Pharmaceutical Proteins: The Opportunities & Pitfalls |
|
|
| New research shows that plants contain many novel carbohydrate-like molecules with valuable therapeutic properties that have been missed in the past. In A New Generation of Carbohydrate Mimic Drugs, Robert Nash, Research Director of Molecular Nature Limited, puts the case for herbal medicines |
|
|
|
| In Measuring Treatment Efficacy in Fronto-temporal Dementia, Dr Barbara Collins, Director of Global Product Development at PRA International, laments the lack of an approved treatment for 'non-Alzheimer' dementia, and deliberates design considerations for future clinical trials |
|
|
| Dr Darren Poinasamy, Business Development Executive at Chiltern International, considers The Future of Drug Delivery in Diabetes - a disease that affects 177 million people worldwide and, more worryingly still, is predicted to reach 300 million by 2025 |
|
|
| Whilst there are a number of novel products in the pipeline, history has shown that the attrition rate of drugs in the respiratory marketplace is high. Shaun Falkingbridge, Respiratory Analyst at Datamonitor, evaluates the potential of The Respiratory Market: A Wealth of Opportunities |
|
|
|
| In SMARTer LIMS - Establishing Global Systems for the Real World, John Boother, Managing Director of Autoscribe Limited, challenges us to revolutionise the working environment within pharma laboratories |
|
|
| Whilst the principles and benefits of measurement uncertainty estimation are well-recognised by the bioanalytical community, few disciplines implement a full measurement uncertainty budget with their results. Dr Malcolm Burns, Biostatistician, Bioanalytical Innovation Team at LGC, examines Bioanalytical Measurements - Attitudes in an Uncertain World |
|
|
|
| Natalie Roy, Product Manager for Cold Chain Solutions at Gemini Data Loggers (UK) Ltd, borrows the concept of an integrated system to achieve a Joined-up Cold Chain: Meeting Stringent Requirements |
|
|
| In Successful Supply Chain Planning in Pharmaceuticals, Matthew Spooner and Eugene Van Dijk, Senior Consultants at World Class International, try to keep us on the side of efficiency |
|
|
|
|
|
 |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
__________________________
__________________________
__________________________
__________________________
|
